#BIO22: The bear mar­ket may be maul­ing biotech stocks, but the fun­da­men­tals still look good to re­al es­tate de­vel­op­ers

The bear mar­ket that has cut the val­u­a­tions of biotech com­pa­nies has not yet af­fect­ed re­al es­tate de­vel­op­ment in life sci­ences, which con­tin­ues to ex­pe­ri­ence a “sus­tained boom,” said Matt Gard­ner, CBRE’s Amer­i­c­as life sci­ences leader.

“We’re ex­pe­ri­enc­ing a sus­tained boom as a re­sult of these dri­vers,” said Gard­ner. “The long IPO win­dow in biotech that went on for a few years. Tens of bil­lions of dol­lars flow­ing in­to the bioe­con­o­my from ad­vanced ma­te­ri­als and fu­ture foods. Ap­pli­ca­tions like bio­plas­tics are one of the biggest dri­vers, and it’s hap­pen­ing at large scale.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.